Trinity Biotech
TRIB
29 hedge funds and large institutions have $16.6M invested in Trinity Biotech in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
38% more call options, than puts
Call options by funds: $586K | Put options by funds: $426K
0.06% more ownership
Funds ownership: 1.29% → 1.36% (+0.06%)
15% less funds holding
Funds holding: 34 → 29 (-5)
18% less capital invested
Capital invested by funds: $20.3M → $16.6M (-$3.67M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$1.37M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$283K |
| 3 |
LPL Financial
San Diego,
California
|
+$126K |
| 4 |
NA
Navellier & Associates
Reno,
Nevada
|
+$62.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$322K |
| 2 |
Millennium Management
New York
|
-$222K |
| 3 |
Squarepoint
New York
|
-$137K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$117K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$106K |
TRIB Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2021, worth a combined $16.6M — down 18% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TRIB and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Hunter Associates Investment Management, adding an estimated $1.37M. The largest seller was Morgan Stanley, cutting an estimated $322K.
- 29 institutional investors held Trinity Biotech (TRIB) as of Q2 2021, down from 34 in Q1 2021.
- Funds reported $16.6M of Trinity Biotech stock for Q2 2021, down 18% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2021 and 8 closed out, a net change of -5 holders.
- The largest Trinity Biotech buyer in Q2 2021 was Hunter Associates Investment Management, an estimated $1.37M added.
- The largest Trinity Biotech seller in Q2 2021 was Morgan Stanley, an estimated $322K sold.
Based on aggregated 13F filings for Q2 2021.